# Insulet Corporation **Source:** https://geo.sig.ai/brands/insulet-corporation **Vertical:** Healthcare Tech **Subcategory:** Enterprise **Tier:** Leader **Website:** insulet.com **Last Updated:** 2026-04-14 ## Summary Acton MA tubeless insulin pump (NASDAQ: PODD) $2.18B FY2024 revenue (+21%); Omnipod 5 automated insulin delivery with Dexcom/Libre integration, type 2 expansion, competing with Medtronic MiniMed and Tandem. ## Company Overview Insulet Corporation is an Acton, Massachusetts-based medical device company — publicly traded on the NASDAQ (NASDAQ: PODD) as an S&P 500 Health Care component — developing, manufacturing, and commercializing the Omnipod insulin delivery system: a tubeless, wearable, waterproof insulin pump patch worn directly on the body without tubing connections to a separate controller, automatically delivering insulin to people with type 1 and type 2 diabetes through approximately 5,000 employees globally. In fiscal year 2024, Insulet reported revenues of $2.18 billion (+21% year-over-year), driven by Omnipod 5 (Omnipod's automated insulin delivery — AID — system integrating with Dexcom CGM and Abbott FreeStyle Libre sensors to automatically adjust insulin delivery based on real-time glucose readings without manual user input), which drove international expansion in Europe and adoption in type 2 diabetes patients who previously used multiple daily injections rather than insulin pumps. CEO Jim Hollingshead has accelerated Omnipod's differentiation through the automated insulin delivery positioning: Omnipod 5's algorithm automatically modulates basal insulin rates every 5 minutes based on continuous glucose monitor readings — reducing A1c levels and time-in-hypoglycemia without requiring the user to manually program correction boluses for most scenarios — transforming diabetes management from active self-management to a background automated process that dramatically improves quality of life for insulin-dependent diabetics. Insulet's tubeless insulin pump model creates competitive advantages through the patient comfort differentiation of Omnipod's patch design versus traditional tubed insulin pumps: conventional insulin pumps (Medtronic MiniMed, Tandem Diabetes t:slim) consist of a hockey-puck-sized pump connected by 24-42 inches of tubing to an infusion set inserted under the skin — requiring the device to be carried in a pocket, attached to clothing, or clipped to a belt, limiting wearability during bathing, swimming, and intimacy. Omnipod's tubeless patch (the size of a small bandage, worn directly on the abdomen, arm, or thigh) eliminates the tubing limitation and the associated social stigma of visible medical devices — enabling discreet insulin delivery that improves therapy adoption and adherence among adults and adolescents who avoided traditional pumps due to tubing inconvenience. The Omnipod consumable business model (patients use a new Pod every 3 days at $30-40 per Pod, generating $3,000-5,000 per patient annually in recurring Pod revenue independent of insulin cost) creates predictable, recurring revenue that grows as the installed base of Omnipod users expands globally. In 2025, Insulet competes in insulin delivery systems and automated insulin delivery against Medtronic (NYSE: MDT, MiniMed 780G AID system), Tandem Diabetes Care (NASDAQ: TNDM, t:slim X2 with Control-IQ algorithm), and Abbott Laboratories (NYSE: ABT, FreeStyle Libre CGM — partnering with Insulet but also competing for diabetes management market share) for insulin pump market share, type 2 diabetes pump adoption, and AID system clinical outcomes positioning. The type 2 diabetes market expansion represents Insulet's largest growth opportunity: the 7-8 million insulin-treated type 2 diabetics in the US who use multiple daily injections represent a conversion opportunity for Omnipod's simplified wearable delivery — requiring clinical evidence that AID benefits in type 2 patients justify premium device cost versus insulin pen injections. Insulet's international expansion (Europe, Japan, Australia) has driven 55%+ of revenue outside the US, with European reimbursement coverage for Omnipod across major health systems (NHS in UK, German GKV, French CPAM) providing structural market access. The 2025 strategy focuses on Omnipod 5 AID international reimbursement expansion, type 2 diabetes clinical outcomes data generation, and next-generation Omnipod platform development (smaller form factor, longer wear time). ## Frequently Asked Questions ### What does Insulet Corporation do? Insulet Corporation develops and manufactures the Omnipod system, a revolutionary tubeless insulin pump that simplifies diabetes management. The company's flagship Omnipod 5 Automated Insulin Delivery System provides up to 3 days of continuous, automated insulin delivery without tubes, needles, or daily injections. The system integrates with continuous glucose monitors to automatically adjust insulin every 5 minutes, helping people with diabetes achieve better glucose control with less effort. ### Who are Insulet's customers and target market? Insulet serves over 500,000 active customers worldwide, including people with Type 1 diabetes (ages 2+) and Type 2 diabetes (ages 18+) who require insulin therapy. The company's target market includes the 6 million people in the U.S. living with insulin-requiring Type 2 diabetes and millions more with Type 1 diabetes globally. Customers range from young children to adults seeking freedom, simplicity, and better diabetes management. ### When was Insulet Corporation founded? Insulet Corporation was founded in July 2000 in Bedford, Massachusetts by John Brooks III, Amparo Diaz, and Duane DeSisto. The company was born from a deeply personal mission when co-founder John Brooks sought a better way to manage his young son's Type 1 diabetes. After more than five years of development and $40 million in R&D investment, Insulet received FDA clearance in 2005 and went public the same year. ### Where is Insulet Corporation headquartered? Insulet Corporation is headquartered in Massachusetts, United States, and operates globally with approximately 3,900 employees. The company has international operations across Europe (including UK, France, Germany, Netherlands), Canada, Australia, Mexico, and the United Arab Emirates, serving customers in markets worldwide. ### How much funding has Insulet raised? Before going public, Insulet raised a total of $120 million in venture capital funding across eight rounds, with major investors including Goldman Sachs, Morgan Stanley, BP, Total, Shell, Deutsche Bank, and Société Générale. The company's Initial Public Offering in November 2005 raised $116 million. As a publicly traded company (NASDAQ: PODD), Insulet now has a market capitalization of approximately $21.66 billion. ### What makes Insulet different from competitors? Insulet's Omnipod is the only tubeless, waterproof insulin pump on the market, eliminating the tubes and complexity of traditional pumps. The Omnipod 5 is the first and only automated insulin delivery system FDA-cleared for both Type 1 and Type 2 diabetes. Unlike competitors, the Pod is controlled wirelessly, is fully disposable (no durable pump to manage), and provides complete freedom for swimming, exercise, and daily activities. The proprietary SmartAdjust algorithm is built directly into the Pod—not in a separate device—for maximum simplicity. ### Who are Insulet's main competitors? Insulet competes with traditional insulin pump manufacturers including Medtronic (MiniMed 780G), Tandem Diabetes Care (t:slim X2), and traditional insulin injection methods. However, Insulet's tubeless design differentiates it from all tubed pump competitors. In the automated insulin delivery market, the company competes with Medtronic's and Tandem's hybrid closed-loop systems, but Omnipod 5 is the only system cleared for both Type 1 and Type 2 diabetes. ### How can I contact Insulet Corporation? Customers can contact Insulet through their official website at www.insulet.com or www.omnipod.com for product information. For investor relations, visit investors.insulet.com. The company's headquarters is located in Massachusetts, and they maintain customer support teams across all markets they serve, providing 24/7 technical support for Omnipod users. ### Is Insulet Corporation hiring? Yes, Insulet is actively growing and hiring across multiple functions and geographies. The company expanded from 3,000 employees in 2023 to 3,900 in 2024 (30% growth) to support rapid business expansion. Career opportunities are available in engineering, manufacturing, sales, marketing, clinical affairs, and corporate functions. Insulet is recognized as a LinkedIn Top Company for employee career development and holds Great Place to Work certifications in eight countries. ### What is the latest news about Insulet? In August 2024, Insulet received FDA clearance for Omnipod 5 for adults with Type 2 diabetes, making it the first automated insulin delivery system approved for both diabetes types. In January 2025, the company reported record 2024 revenue of $2.07 billion (22% growth) and surpassed 500,000 global customers—marking the ninth consecutive year of 20%+ growth. In April 2025, Ashley McEvoy was appointed as new CEO, bringing 27 years of Johnson & Johnson MedTech leadership experience. ### What is Insulet's market position? Insulet is the global leader in tubeless insulin pump technology and a major player in automated insulin delivery. The company has achieved nine consecutive years of 20% or greater revenue growth, reaching $2.07 billion in 2024 revenue with 69.8% gross margins. With 365,000 active Omnipod 5 users and approval for both Type 1 and Type 2 diabetes, Insulet has a significant competitive advantage in the rapidly growing $8+ billion insulin delivery market. ### What are Insulet's future plans? Insulet is developing the Omnipod Fully Closed Loop system for Type 2 diabetes—the first out-of-the-box, fully automated insulin delivery system requiring no meal announcements or carb counting. The company is also planning upgrades to Omnipod 5 to strengthen glycemic control, improve usability, and expand ecosystem connectivity. Internationally, Insulet continues expanding in Europe and other markets while pursuing Type 2 diabetes approvals globally to capitalize on the 6 million patient opportunity. ## Tags b2b, healthtech, manufacturing, saas, public --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*